Remestemcel-L
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Grade B Acute Graft Versus Host Disease
Conditions
Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease
Trial Timeline
Oct 28, 2015 โ Jun 15, 2018
NCT ID
NCT02652130About Remestemcel-L
Remestemcel-L is a phase 3 stage product being developed by Mesoblast for Grade B Acute Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02652130. Target conditions include Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04366830 | Pre-clinical | Completed |
| NCT00759018 | Pre-clinical | Completed |
| NCT02652130 | Phase 3 | Completed |
| NCT02336230 | Phase 3 | Completed |
Competing Products
20 competing products in Grade B Acute Graft Versus Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-ฮฑ-NET | Perspective Therapeutics | Phase 1 | 25 |
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 52 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Letrozole | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib + Mosunetuzumab | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Mirvetuximab soravtansine + Carboplatin | AbbVie | Phase 2 | 52 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Acalabrutinib + Obinutuzumab | AstraZeneca | Phase 2 | 52 |
| Olaparib Pill + AZD6738 | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Efineptakin alfa + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| Cilengitide | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
Other Products from Mesoblast
Remestemcel-L + PlaceboPhase 3
72
Rexlemestrocel-L + HA mixture + SalinePhase 3
72
Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units.Phase 3
72
Prochymalยฎ + Placebo + Standard of Care for GVHDPhase 3
72
Placebo + PROCHYMAL adult human mesenchymal stem cellsPhase 3
72